GlassScriptPhysician profile
Anne Hardart
NPI 1104827583
$8,008.99
in general payments reported to CMS, 2019-2025
13 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $158 · 2021: $206 · 2022: $208 · 2023: $6,161 · 2024: $756 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,500 · Food and Beverage: $1,673 · Travel and Lodging: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,500.00 |
| Food and Beverage | $1,673.34 |
| Travel and Lodging | $1,037.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,790.50 | 2023-2025 | Axonics, Solyx Sis System, Capio Rp |
| Coloplast Corp | $1,133.23 | 2019-2024 | Altis |
| Femselect INC. | $237.81 | 2025 | Enplace |
| Escala Medical INC. | $167.76 | 2024 | |
| Gynesonics, INC. | $147.83 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Medtronic, INC. | $145.02 | 2023 | Interstim |
| Axonics, INC. | $109.82 | 2023 | Bulkamid |
| Abbvie INC. | $89.36 | 2022-2023 | |
| Applied Medical Resources Corporation | $71.35 | 2023 | |
| Renovia INC | $67.62 | 2019 | |
| Amag Pharmaceuticals, INC. | $20.95 | 2019 | |
| Hologic Sales and Service, LLC | $16.76 | 2021 | |
| Pfizer INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Hardart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.